查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
欧洲影像导引药物传输市场（按技术类型、应用、最终用户和国家划分）分析与预测（2025 年至 2035 年）
市场调查报告书
商品编码
1847082

欧洲影像导引药物传输市场（按技术类型、应用、最终用户和国家划分）分析与预测（2025 年至 2035 年）

Europe Image-Guided Drug Delivery Market: Focus on Technology Type, Application, End User, and Country Analysis - Analysis and Forecast, 2025-2035
出版日期: | 出版商: BIS Research | 英文 65 Pages | 商品交期: 1-5个工作天内

价格

预计到 2035 年，欧洲影像导引药物传输市场规模将达到 2.841 亿美元，高于 2024 年的 1,370 万美元，在 2025-2035 年预测期内的复合年增长率为 32.01%。

在欧洲，影像导引药物传递 (IGDD) 采用先进且精准的微创技术，将治疗药物直接输送至肿瘤和神经系统等患病区域。这种创新策略代表着从传统的全身性治疗转变为更针对患者、更局部、更安全的方法的转变。 IGDD 利用机器人技术和人工智慧导航，将导管和套管等专用输送工具与 MRI、CT 和超音波等成像平台相结合，使医生能够以惊人的精度实施化疗、基因治疗和细胞疗法。这项技术改善了治疗效果，降低了全身毒性，加快了康復速度，并最大限度地提高了医疗效益，使 IGDD 成为欧洲精准医疗的重要组成部分。

主要市场统计数据
预测期 2025-2035
2025年评估 1770万美元
2035年的预测 2.841亿美元
复合年增长率 32.01%

市场介绍

IGDD 系统的使用正在欧洲各地不断扩展，先进成像药物传输技术的开发正推动欧洲市场的爆炸性成长。透过将药物精准输送至肿瘤或脑区等特定疾病部位，这些设备可以降低全身毒性并改善患者预后。欧洲对标靶药物输送和精准医疗日益增长的需求推动了对结合 MRI、CT、PET 和超音波影像与微创治疗的尖端药物输送平台的投资。

在欧洲，影像导引药物传递应用主要集中在肿瘤科、神经科和创伤治疗领域，由于癌症发生率上升，肿瘤科的应用尤其突出。欧洲人口老化、慢性病发病率上升以及影像引导药物输送技术的不断改进，都促进了市场的扩张。此外，由于政府对医疗创新的资金投入和监管支持，IGDD 系统在欧洲的普及速度更快，使其成为下一代精准医疗解决方案的关键组成部分。

德国、法国和英国凭藉其在精准靶向给药技术方面的巨额研发投入和完善的医疗基础设施，在欧洲影像引导给药产业中占据主导地位。由于医疗保健管道的改善和医疗意识的提升，东欧新兴国家对影像引导给药系统的采用也日益增加。然而，高昂的前期成本、复杂的法规、技术限制以及对患者资料隐私的担忧等因素，仍然是市场渗透和广泛应用的阻碍。

预计未来十年，欧洲靶向药物输送市场将迎来强劲成长，这得益于持续的技术进步以及对个人化药物输送日益增长的关注。主导导航、机器人技术和影像技术的整合将提高治疗精准度，缩短復原时间，并优化医疗资源，使欧洲成为下一代精准医疗和标靶药物输送解决方案的领导者。

市场区隔

细分 1：按技术类型

  • 药物输送系统
  • 影像引导平台

细分2：按应用

  • 肿瘤学
  • 神经病学
  • 其他的

细分 3：按最终用户

  • 医院
  • 製药和生物技术公司
  • 委外研发机构（CRO）
  • 科学研究院所及大学

细分4：按地区

  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 其他的

欧洲影像导引药物传输市场趋势、驱动因素与挑战

市场趋势

  • 技术进步：MRI、CT、PET 和超音波等显像模式与药物传递系统的结合提高了治疗的精确度和疗效，特别是在肿瘤学和神经病学领域。
  • 微创手术：人们越来越倾向于微创手术，并且越来越多地采用影像引导疗法，从而缩短恢復时间并改善患者的治疗效果。
  • 个人化医疗：向个人化治疗计划的转变正在推动针对个人患者情况的 IGDD 系统的开发和采用。
  • 监管支援：欧洲监管机构为创新药物输送技术的核准提供了明确的途径，促进了市场成长。

市场驱动因素

  • 慢性病发病率上升：癌症和神经系统疾病等疾病的发生率不断上升，推动了对有针对性和有效治疗方案的需求。
  • 成像技术的进步：显像模式的不断改进提高了 IGDD 系统的准确性和可靠性，使其对医疗保健提供者更具吸引力。
  • 人口老化：欧洲人口老化和与老龄化相关的疾病发病率上升推动了对先进药物输送解决方案的需求。
  • 医疗保健基础设施：欧洲拥有发达的医疗基础设施和高水准的医疗专业知识，从而引入了先进的药物输送系统。
  • 政府措施：政府的支持性政策和对医学研究的资助正在加速 IGDD 技术的开发和应用。

市场挑战

  • 高成本：IGDD 系统的初始投资和维护成本可能很高，限制了其使用，尤其是在较小的医疗机构中。
  • 监管障碍：医疗设备和药物输送系统复杂的监管环境可能会减缓市场进入和采用的速度。
  • 技术限制：整合影像处理和药物传输技术所带来的挑战以及设备校准和标准化问题可能会影响 IGDD 系统的有效性。
  • 患者意识：患者对 IGDD 治疗的认识和理解有限可能会阻碍他们接受和利用这些先进的治疗方法。
  • 资料隐私问题：在药物输送中使用影像资料引发了对病患资料隐私和安全的担忧，需要严格遵守资料保护条例。

产品/创新策略：本报告深入探讨了影像导引药物传输领域的最新技术进步，使公司能够推动创新并开发出满足市场需求的尖端产品。

成长/行销策略：透过提供全面的市场分析和识别关键的成长机会，公司能够获得制定有针对性的行销策略和有效扩大其市场占有率的知识。

竞争策略：透过对竞争格局的彻底分析，我们了解您的竞争对手的优势和劣势，并帮助您制定有效的策略以在市场上获得竞争优势。

监管和合规策略：提供有关不断发展的法律规范、核准和行业指南的最新信息，以使公司能够保持合规并加速新型图像引导药物输送解决方案的市场进入。

投资和业务扩大策略：透过分析市场趋势、资金筹措模式和合作机会，我们帮助公司做出明智的投资决策并确定业务成长的潜在併购机会。

主要市场参与企业和竞争对手的摘要

公司简介是根据从主要专家收集的意见以及对公司覆盖范围、产品系列和市场渗透率的分析而选择的。

该市场的一些知名参与者包括：

  • Renishaw plc.
  • Neurochase
  • Koninklijke Philips NV

目录

执行摘要

第一章市场：产业展望

  • 竞争格局
  • 产业展望
    • 趋势、驱动因素、挑战与机会：现状与未来影响评估，2024-2035
    • 市场趋势
    • 影像导引药物传递的进展
    • 影像导引药物传递的未来方向和新兴技术
  • 市场动态

第二章 区域

  • 区域摘要
  • 欧洲
    • 区域概况
    • 市场成长动力
    • 成长抑制因素
    • 依技术类型
    • 按用途
    • 按最终用户
    • 按国家

第三章 市场-公司简介

  • 公司简介
    • Renishaw plc.
    • Neurochase
    • Koninklijke Philips NV

第四章调查方法

Product Code: BHL3344SS

This report can be delivered in 2 working days.

Introduction to Europe Image-Guided Drug Delivery Market

The Europe image-guided drug delivery market is projected to reach $284.1 million by 2035 from $13.7 million in 2024, growing at a CAGR of 32.01% during the forecast period 2025-2035. Therapeutics are delivered directly to illness areas, such as tumors and neurological regions, in Europe through Image-Guided Drug Delivery (IGDD), which uses sophisticated, precision-focused, minimally invasive procedures. This novel strategy represents a change from traditional systemic treatments to more patient-specific, localized, and safe approaches. With the use of robots and AI-guided navigation, IGDD enables physicians to deliver chemotherapeutics, gene therapies, and cell-based treatments with remarkable precision by fusing specialized delivery tools like catheters and cannulae with imaging platforms like MRI, CT, and ultrasound. The technique improves treatment results, lowers systemic toxicity, speeds up recuperation, and maximizes healthcare effectiveness, making IGDD a crucial component of Europe's precision medicine scene.

KEY MARKET STATISTICS
Forecast Period2025 - 2035
2025 Evaluation$17.7 Million
2035 Forecast$284.1 Million
CAGR32.01%

Market Introduction

The growing use of IGDD systems throughout Europe and developments in sophisticated imaging drug delivery technologies are fueling the market's explosive expansion in Europe. By precisely delivering medications to specific disease sites, such as tumors and brain areas, these devices lower systemic toxicity and enhance patient outcomes. Investments in cutting-edge drug delivery platforms that combine MRI, CT, PET, and ultrasound imaging with minimally invasive treatments are being driven by the rising need for targeted medication delivery and precision medicine in Europe.

In Europe, image-guided drug delivery applications are predominantly seen in oncology, neurology, and wound healing, with oncology leading due to rising cancer prevalence. The aging of Europe's population, the rise in chronic illnesses, and continuous improvements in imaging-guided drug delivery technologies all contribute to the market's expansion. Additionally, IGDD systems are being adopted more quickly in Europe thanks to government financing for healthcare innovation and favorable regulatory support, making these technologies a crucial component of next-generation precision medicine solutions.

With substantial R&D expenditures in precision-targeted drug delivery technology and established healthcare infrastructure, Germany, France, and the United Kingdom dominate the European image-guided drug delivery industry. Because of increased access to and awareness of healthcare, emerging economies in Eastern Europe are progressively implementing IGDD systems. However, obstacles including high upfront costs, complicated regulations, technical constraints, and privacy concerns about patient data still hinder market penetration and broad adoption.

The Europe IGDD market is projected to achieve strong growth over the next decade, driven by continuous technological advancements and the increasing emphasis on personalized drug delivery. Integrating AI-driven navigation, robotics, and imaging technologies will enhance therapeutic precision, reduce recovery times, and optimize healthcare resources, positioning Europe as a leader in next-generation precision medicine and targeted drug delivery solutions.

Market Segmentation:

Segmentation 1: By Technology Type

  • Drug-Delivery Systems
  • Image-Guided Platforms

Segmentation 2: By Application

  • Oncology
  • Neurology
  • Others

Segmentation 3: By End User

  • Hospitals
  • Pharmaceutical & Biotechnology Companies
  • Contract Research Organizations (CROs)
  • Research Institutes & Universities

Segmentation 4: By Region

  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest-of-Europe

Europe Image-Guided Drug Delivery Market Trends, Drivers and Challenges

Market Trends

  • Technological Advancements: Integration of imaging modalities such as MRI, CT, PET, and ultrasound with drug delivery systems is enhancing the precision and efficacy of treatments, particularly in oncology and neurology.
  • Minimally Invasive Procedures: There is a growing preference for minimally invasive techniques, leading to increased adoption of image-guided therapies that offer reduced recovery times and improved patient outcomes.
  • Personalized Medicine: The shift towards personalized treatment plans is fostering the development and adoption of IGDD systems tailored to individual patient profiles.
  • Regulatory Support: European regulatory bodies are providing clearer pathways for the approval of innovative drug delivery technologies, facilitating market growth.

Market Drivers

  • Rising Incidence of Chronic Diseases: The increasing prevalence of conditions such as cancer and neurological disorders is driving demand for targeted and effective treatment options.
  • Advancements in Imaging Technologies: Continuous improvements in imaging modalities are enhancing the accuracy and reliability of IGDD systems, making them more appealing to healthcare providers.
  • Aging Population: Europe's aging demographic is contributing to a higher incidence of age-related diseases, thereby increasing the need for advanced drug delivery solutions.
  • Healthcare Infrastructure: Well-established healthcare infrastructure and a high level of medical expertise in Europe are conducive to the adoption of advanced drug delivery systems.
  • Government Initiatives: Supportive government policies and funding for medical research are accelerating the development and implementation of IGDD technologies.

Market Challenges

  • High Costs: The initial investment and maintenance costs of IGDD systems can be prohibitive, limiting their accessibility, especially in smaller healthcare facilities.
  • Regulatory Hurdles: Navigating the complex regulatory landscape for medical devices and drug delivery systems can delay market entry and adoption.
  • Technical Limitations: Challenges related to the integration of imaging and drug delivery technologies, as well as issues with device calibration and standardization, can impact the effectiveness of IGDD systems.
  • Patient Awareness: Limited patient awareness and understanding of IGDD therapies can hinder acceptance and utilization of these advanced treatment options.
  • Data Privacy Concerns: The use of imaging data in drug delivery raises concerns regarding patient data privacy and security, necessitating stringent compliance with data protection regulations.

How can this report add value to an organization?

Product/Innovation Strategy: The report offers in-depth insights into the latest technological advancements in Image-Guided Drug Delivery, enabling organizations to drive innovation and develop cutting-edge products tailored to market needs.

Growth/Marketing Strategy: By providing comprehensive market analysis and identifying key growth opportunities, the report equips organizations with the knowledge to craft targeted marketing strategies and expand their market presence effectively.

Competitive Strategy: The report includes a thorough competitive landscape analysis, helping organizations understand their competitors' strengths and weaknesses and allowing them to strategize effectively to gain a competitive edge in the market.

Regulatory and Compliance Strategy: It provides updates on evolving regulatory frameworks, approvals, and industry guidelines, ensuring organizations stay compliant and accelerate market entry for new Image-Guided Drug Delivery

Investment and Business Expansion Strategy: By analyzing market trends, funding patterns, and partnership opportunities, the report assists organizations in making informed investment decisions and identifying potential M&A opportunities for business growth.

Key Market Players and Competition Synopsis

Profiled companies have been selected based on inputs gathered from primary experts, as well as analyzing company coverage, product portfolio, and market penetration.

Some prominent names established in this market are:

  • Renishaw plc.
  • Neurochase
  • Koninklijke Philips N.V.

Table of Contents

Executive Summary

Scope and Definition

1 Market: Industry Outlook

  • 1.1 Competitive Landscape
  • 1.2 Industry Outlook
    • 1.2.1 Trends, Drivers, Challenges, and Opportunities: Current and Future Impact Assessment, 2024-2035
    • 1.2.2 Market Trends
      • 1.2.2.1 Integration of Imaging with Targeted Drug Delivery
    • 1.2.3 Advancements in Image-Guided Drug Delivery
    • 1.2.4 Future Direction and Emerging Technologies in Image-Guided Drug Delivery
  • 1.3 Market Dynamics
    • 1.3.1 Impact Analysis
    • 1.3.2 Market Driver
      • 1.3.2.1 Increased Demand for Personalized Medicine
      • 1.3.2.2 Rising Prevalence of Chronic Diseases
      • 1.3.2.3 Technological Advancements in Image-Guided Drug Delivery
    • 1.3.3 Market Restraint
      • 1.3.3.1 High Acquisition Cost of the Instruments
    • 1.3.4 Market Opportunity
      • 1.3.4.1 Integration of Artificial Intelligence in Image-Guided Drug Delivery

2 Region

  • 2.1 Regional Summary
  • 2.2 Europe
    • 2.2.1 Regional Overview
    • 2.2.2 Driving Factors for Market Growth
    • 2.2.3 Factors Challenging the Market
    • 2.2.4 By Technology Type
    • 2.2.5 By Application
    • 2.2.6 By End User
    • 2.2.7 By Country
      • 2.2.7.1 U.K.
    • 2.2.8 By Technology Type
    • 2.2.9 By Application
    • 2.2.10 By End User
      • 2.2.10.1 Germany
    • 2.2.11 By Technology Type
    • 2.2.12 By Application
    • 2.2.13 By End User
      • 2.2.13.1 France
    • 2.2.14 By Technology Type
    • 2.2.15 By Application
    • 2.2.16 By End User
      • 2.2.16.1 Italy
    • 2.2.17 By Technology Type
    • 2.2.18 By Application
    • 2.2.19 By End User
      • 2.2.19.1 Spain
    • 2.2.20 By Technology Type
    • 2.2.21 By Application
    • 2.2.22 By End User
      • 2.2.22.1 Rest-of-Europe
    • 2.2.23 By Technology Type
    • 2.2.24 By Application
    • 2.2.25 By End User

3 Markets - Company Profiles

  • 3.1 Company Profiles
    • 3.1.1 Renishaw plc.
      • 3.1.1.1 Overview
      • 3.1.1.2 Pipeline Product Portfolio
      • 3.1.1.3 Top Competitors
      • 3.1.1.4 Target Customers
      • 3.1.1.5 Key Personnel
      • 3.1.1.6 Analyst View
      • 3.1.1.7 Renishaw plc., Revenue ($Million), 2022-2024
    • 3.1.2 Neurochase
      • 3.1.2.1 Overview
      • 3.1.2.2 Pipeline Product Portfolio
      • 3.1.2.3 Top Competitors
      • 3.1.2.4 Target Customers
      • 3.1.2.5 Key Personnel
      • 3.1.2.6 Analyst View
    • 3.1.3 Koninklijke Philips N.V.
      • 3.1.3.1 Overview
      • 3.1.3.1 Top Products/Product Portfolio
      • 3.1.3.2 Top Competitors
      • 3.1.3.3 Target Customers
      • 3.1.3.4 Key Personnel
      • 3.1.3.5 Analyst View

4 Research Methodology

  • 4.1 Data Sources
    • 4.1.1 Primary Data Sources
    • 4.1.2 Secondary Data Sources
    • 4.1.3 Data Triangulation
  • 4.2 Market Estimation and Forecast

List of Figures

  • Figure 1: Europe Image-Guided Drug Delivery Market (by Scenario), $Million, 2024, 2030, and 2035
  • Figure 2: Europe Image-Guided Drug Delivery Market, 2024 and 2035
  • Figure 3: Europe Image-Guided Drug Delivery Market Snapshot
  • Figure 4: Image-Guided Drug Delivery Market, $Million, 2024 and 2035
  • Figure 5: Europe Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024, 2030, and 2035
  • Figure 6: Europe Image-Guided Drug Delivery Market (by Application), $Million, 2024, 2030, and 2035
  • Figure 7: Europe Image-Guided Drug Delivery Market (by End User), $Million, 2024, 2030, and 2035
  • Figure 8: Europe Image-Guided Drug Delivery Market Segmentation
  • Figure 9: U.K. Image-Guided Drug Delivery Market, $Million, 2024-2035
  • Figure 10: Germany Image-Guided Drug Delivery Market, $Million, 2024-2035
  • Figure 11: France Image-Guided Drug Delivery Market, $Million, 2024-2035
  • Figure 12: Italy Image-Guided Drug Delivery Market, $Million, 2024-2035
  • Figure 13: Spain Image-Guided Drug Delivery Market, $Million, 2024-2035
  • Figure 14: Rest-of-Europe Image-Guided Drug Delivery Market, $Million, 2024-2035
  • Figure 15: Data Triangulation
  • Figure 16: Top-Down and Bottom-Up Approach
  • Figure 17: Assumptions and Limitations

List of Tables

  • Table 1: Market Snapshot
  • Table 2: Image-Guided Drug Delivery Market (by Region), $Million, 2024-2035
  • Table 3: Europe Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024-2035
  • Table 4: Europe Image-Guided Drug Delivery Market (by Application), $Million, 2024-2035
  • Table 5: Europe Image-Guided Drug Delivery Market (by End User), $Million, 2024-2035
  • Table 6: U.K. Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024-2035
  • Table 7: U.K. Image-Guided Drug Delivery Market (by Application), $Million, 2024-2035
  • Table 8: U.K. Image-Guided Drug Delivery Market (by End User), $Million, 2024-2035
  • Table 9: Germany Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024-2035
  • Table 10: Germany Image-Guided Drug Delivery Market (by Application), $Million, 2024-2035
  • Table 11: Germany Image-Guided Drug Delivery Market (by End User), $Million, 2024-2035
  • Table 12: France Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024-2035
  • Table 13: France Image-Guided Drug Delivery Market (by Application), $Million, 2024-2035
  • Table 14: France Image-Guided Drug Delivery Market (by End User), $Million, 2024-2035
  • Table 15: Italy Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024-2035
  • Table 16: Italy Image-Guided Drug Delivery Market (by Application), $Million, 2024-2035
  • Table 17: Italy Image-Guided Drug Delivery Market (by End User), $Million, 2024-2035
  • Table 18: Spain Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024-2035
  • Table 19: Spain Image-Guided Drug Delivery Market (by Application), $Million, 2024-2035
  • Table 20: Spain Image-Guided Drug Delivery Market (by End User), $Million, 2024-2035
  • Table 21: Rest-of-Europe Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024-2035
  • Table 22: Rest-of-Europe Image-Guided Drug Delivery Market (by Application), $Million, 2024-2035
  • Table 23: Rest-of-Europe Image-Guided Drug Delivery Market (by End User), $Million, 2024-2035